Pfizer's Options: A Look at What the Big Money is Thinking
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from ...
The Pharma Letter2 日
Pfizer agrees ~$60 million false claims settlement over Nurtec ODT
The US Department of Justice announced Friday that Pfizer has agreed in New York federal court to pay $59.7 million to ...
The Pharma Letter2 日
Positive Phase III results for Pfizer’s Braftovi combo
US pharma giant Pfizer on Saturday announced positive results from the Phase III BREAKWATER trial evaluating its Braftovi ...
Why Pfizer sold its $3 billion stake in Haleon
Pfizer divests $3.05 billion of Haleon shares, cutting its stake to 7.3% in a strategic shift to refocus on core pharmaceutical operations.
Nature17 日
Pfizer dumps Exubera
After 11 years of development and barely one full year of sales, New York–based Pfizer dumped the much-anticipated inhaled powder insulin product Exubera on 18 October. This was particularly bad ...